Ribonucleotide reductase subunit switching in hepatoblastoma drug response and relapse
In hepatoblastoma, the RRM2 subunit of ribonucleotide reductase is associated with disease progression, but in response to chemotherapy, subunit switching favours the less active RRM2B subunit which supports hepatoblastoma cell survival and relapse.
Main Authors: | Anthony Brown, Qingfei Pan, Li Fan, Emilie Indersie, Cheng Tian, Nikolai Timchenko, Liyuan Li, Baranda S. Hansen, Haiyan Tan, Meifen Lu, Junmin Peng, Shondra M. Pruett-Miller, Jiyang Yu, Stefano Cairo, Liqin Zhu |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-03-01
|
Series: | Communications Biology |
Online Access: | https://doi.org/10.1038/s42003-023-04630-7 |
Similar Items
-
Targeting the Large Subunit of Human Ribonucleotide Reductase for Cancer Chemotherapy
by: Prem Singh Kaushal, et al.
Published: (2011-10-01) -
Deciphering Radical Transport in the Large Subunit of Class I Ribonucleotide Reductase
by: Stubbe, JoAnne, et al.
Published: (2013) -
Ribonucleotide reductase requires subunit switching in hypoxia to maintain DNA replication
by: Foskolou, I, et al.
Published: (2017) -
Ribonucleotide reductase requires subunit switching in hypoxia to maintain DNA replication.
by: Foskolou, IP, et al.
Published: (2017) -
Gated Proton Release during Radical Transfer at the Subunit Interface of Ribonucleotide Reductase
by: Cui, Chang, et al.
Published: (2022)